New Long-Acting HIV prevention shot enters human safety trials
NCT ID NCT06724640
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new long-acting injectable drug, VH4011499, in 168 healthy adults without HIV. The goal is to see if it is safe and how the body processes it, as a potential future option for HIV prevention. Participants receive one or more doses of the drug or a placebo and are monitored for side effects and drug levels in the blood.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
GSK Investigational Site
RECRUITINGLas Vegas, Nevada, 89113, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
GSK Investigational Site
RECRUITINGAustin, Texas, 78744, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Peer-led prevention: can gancheros help stop HIV, hepatitis c, and overdose in NYC?
- Small cash rewards may keep HIV-positive mothers in treatment — a trial puts the idea to the test
- Long-acting HIV shot studied in patients with severe kidney problems
- Can two hours of mindfulness ease chronic pain in HIV patients?
- Can a clinic-and-social-media campaign boost HIV prevention among black women?
- Choice of Long-Acting HIV prevention could transform care for young people in rural south africa